Statistical motion modelling for robust evaluation of clinically delivered accumulated dose distributions after curative radiotherapy of locally advanced prostate cancer

被引:8
|
作者
Hysing, Liv B. [1 ,2 ]
Ekanger, Christian [1 ]
Zolnay, Andras [3 ]
Helle, Svein Inge [1 ]
Rasi, Mana [1 ]
Heijmen, Ben J. M. [3 ]
Sikora, Marcin [1 ]
Soehn, Matthias [4 ]
Muren, Ludvig Paul [5 ]
Thornqvist, Sara [1 ,2 ]
机构
[1] Haukeland Hosp, Dept Oncol & Med Phys, Jonas Lies Vei 65, NO-5021 Bergen, Norway
[2] Univ Bergen, Dept Phys & Technol, Bergen, Norway
[3] Erasmus MC, Inst Canc, Dept Radiat Oncol, Rotterdam, Netherlands
[4] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Munich, Germany
[5] Aarhus Univ Hosp, Dept Med Phys, Aarhus, Denmark
关键词
Dose accumulation; Organ motion; Prostate; Robustness; Image-guided; Intensity modulated radiotherapy (IMRT); MORBIDITY FOLLOWING RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; ORGAN MOTION; RADIATION-THERAPY; ADAPTIVE RADIOTHERAPY; PELVIC RADIOTHERAPY; NORMAL TISSUE; GEOMETRIC UNCERTAINTIES; NONRIGID REGISTRATION; VOLUME HISTOGRAMS;
D O I
10.1016/j.radonc.2018.06.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Planned doses are used as surrogate for the actually delivered dose in radiotherapy. We have estimated the delivered dose in a dose-escalation trial of locally advanced prostate cancer by statistical dose-accumulation and by DVH-summation, and compared to planned dose. Materials and method: Prescribed dose-escalation to the prostate was 67.5 Gy/25fr., corresponding to 81GyEQD2 assuming alpha/beta = 1.5. The 21 patients had three targets (i.e. CTV67.5 + 2 mm, CTV60 + 5 mm, CTV50 + 10 mm) irradiated by a simultaneous-integrated-boost technique. Analysis was based on 213 CT scans and 5-years of follow-up. For statistical dose-accumulation, we modelled 10000 possible treatment courses based on planned dose and deformation-vector-fields from contour-based registration. For DVH-summation we recalculated dose on repeat-CTs and estimated median D98%/EUD. Groups with/without disease recurrence were compared. Results: Discrepancies between planned and accumulated dose were mostly seen for CTV67.5, where under-dosage was found at different locations in the prostate in 12/21 patients. Delivered dose-escalation (D98%) was on average 73.9GyEQD2 (range: 68.3-78.7GyEQD2). No significant difference in accumulated-D98% was found in patients with (n = 8) and without (n = 13) recurrence (p > 0.05). Average D98%/EUD with statistical dose-accumulation vs DVH-summation was significantly different in CTV60, CTV50, rectum and bladder but not in CTV67.5. Conclusion: The planned dose escalation was not received by more than half-of-the patients. Robustness of the prostate target (CTV67.5) should therefore be better prioritized in these patients given the low toxicity profile. Estimates of delivered dose were less conservative for dose-accumulation due to interaction of random organ motion with the dose matrix. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 50 条
  • [1] Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer
    Kim, Sunghyun
    Kong, Jee Hyun
    Lee, YoHan
    Lee, Jun Young
    Kang, Tae Wook
    Kong, Tae Hoon
    Kim, Myung Ha
    You, Sei Hwan
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (03):
  • [2] Adaptive radiotherapy in locally advanced prostate cancer using a statistical deformable motion model
    Thornqvist, Sara
    Hysing, Liv B.
    Zolnay, Andras G.
    Sohn, Matthias
    Hoogeman, Mischa S.
    Muren, Ludvig P.
    Heijmen, Ben J. M.
    [J]. ACTA ONCOLOGICA, 2013, 52 (07) : 1423 - 1429
  • [3] High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?
    Matthew D Galsky
    William Kevin Kelly
    [J]. Nature Clinical Practice Urology, 2007, 4 : 134 - 135
  • [4] High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?
    Galsky, Matthew D.
    Kelly, William Kevin
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (03): : 134 - 135
  • [5] Late toxicity predictors in high-risk prostate cancer radiotherapy using accumulated delivered dose
    Ong, A.
    Panettieri, V.
    Dimmock, M.
    Tuan, J.
    Tan, H. Q.
    Wright, C.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1905 - S1906
  • [6] High Dose Rate and External Beam Radiotherapy in Locally Advanced Prostate Cancer
    Viani, Gustavo Arruda
    Pellizzon, Antonio Cassio
    Guimaraes, Flavio Silva
    Jacinto, Alexandre Arthur
    Ribeiro dos Santos Novaes, Paulo Eduardo
    Salvajoli, Joao Vitor
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (02): : 187 - 190
  • [7] ORGAN MOTION CORRECTION WITH PATIENT SHIFTING DURING PROSTATE CANCER RADIOTHERAPY: EFFECT ON DELIVERED DOSE
    Kovacs, P.
    Sebestyen, Z.
    Farkas, R.
    Bellyei, S.
    Derczy, K.
    Szigeti, A.
    Liposits, G.
    Gulyban, A.
    Esik, O.
    Mangel, L.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S388 - S388
  • [8] Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: Results of a dose escalation study
    Forman, JD
    Duclos, M
    Shamsa, F
    Porter, AT
    Orton, C
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (03): : 655 - 662
  • [9] Chemoradiotherapy for locally advanced pancreatic cancer: a radiotherapy dose escalation and organ motion study
    Henry, A. M.
    Ryder, W. D. J.
    Moore, C.
    Sherlock, D. J.
    Geh, J. I.
    Dunn, P.
    Price, P.
    [J]. CLINICAL ONCOLOGY, 2008, 20 (07) : 541 - 547
  • [10] LATE EFFECTS AFTER RADIOTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER: COMPARISON OF TWO BRACHYTHERAPY SCHEDULES AND EFFECT OF DOSE DELIVERED WEEKLY
    Hellebust, Taran Paulsen
    Kristensen, Gunnar B.
    Olsen, Dag Rune
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : 713 - 718